These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 36878698)
1. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Alcolea D; Beeri MS; Rojas JC; Gardner RC; Lleó A Neurology; 2023 Jul; 101(4):172-180. PubMed ID: 36878698 [TBL] [Abstract][Full Text] [Related]
2. Biomarkers for neurodegenerative diseases. Hansson O Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604 [TBL] [Abstract][Full Text] [Related]
4. Blood biomarkers of neuronal injury in paediatric cerebral malaria and severe malarial anaemia. Datta D; Gopinadhan A; Soto A; Bangirana P; Opoka RO; Conroy AL; Saykin AJ; Kawata K; John CC Brain Commun; 2023; 5(6):fcad323. PubMed ID: 38075948 [TBL] [Abstract][Full Text] [Related]
5. Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases. Park Y; Kc N; Paneque A; Cole PD Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928000 [TBL] [Abstract][Full Text] [Related]
6. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Sengupta U; Kayed R Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272 [TBL] [Abstract][Full Text] [Related]
7. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia. Kuchenbecker LA; Tipton PW; Martens Y; Brier MR; Satyadev N; Dunham SR; Lazar EB; Dacquel MV; Henson RL; Bu G; Geschwind MD; Morris JC; Schindler SE; Herries E; Graff-Radford NR; Day GS Ann Neurol; 2024 Feb; 95(2):299-313. PubMed ID: 37897306 [TBL] [Abstract][Full Text] [Related]
14. Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study. Perna L; Stocker H; Burow L; Beyer L; Trares K; Kurz C; Gürsel S; Holleczek B; Tatò M; Beyreuther K; Mons U; Gerwert K; Perneczky R; Schöttker B; Brenner H Alzheimers Res Ther; 2023 Nov; 15(1):198. PubMed ID: 37951931 [TBL] [Abstract][Full Text] [Related]
15. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. Obrocki P; Khatun A; Ness D; Senkevich K; Hanrieder J; Capraro F; Mattsson N; Andreasson U; Portelius E; Ashton NJ; Blennow K; Schöll M; Paterson RW; Schott JM; Zetterberg H Alzheimers Res Ther; 2020 Feb; 12(1):20. PubMed ID: 32111242 [TBL] [Abstract][Full Text] [Related]